Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.85 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | NR2E3 | Q9Y5X4 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249424 | 0.93 | DGAT1 (0.82) | DGAT1CHEK2KDRNR2E3CYP3A4 | |
| SCHEMBL1248774 | 0.92 | DGAT1 (1.00) | DGAT1CHEK2KDRNR2E3CYP3A4 | |
| SCHEMBL1249930 | 0.91 | DGAT1 (0.85) | DGAT1CHEK2NR2E3CYP3A4ITGB1 | |
| SCHEMBL1250413 | 0.90 | DGAT1 (0.77) | DGAT1CHEK2KDRNR2E3CYP3A4 | |
| SCHEMBL1251669 | 0.90 | DGAT1 (0.77) | DGAT1CHEK2KDRNR2E3CYP3A4 | |
| SCHEMBL1249997 | 0.89 | DGAT1 (0.82) | DGAT1CHEK2KDRMAOBNR2E3 | |
| SCHEMBL1250649 | 0.88 | DGAT1 (0.80) | DGAT1CHEK2KDRMAOBNR2E3 | |
| SCHEMBL1251070 | 0.88 | DGAT1 (0.80) | DGAT1CHEK2KDRMAOBNR2E3 | |
| SCHEMBL1251547 | 0.88 | DGAT1 (0.84) | DGAT1CHEK2KDRNR2E3CHEK1 | |
| SCHEMBL1251539 | 0.88 | DGAT1 (0.84) | DGAT1CHEK2KDRNR2E3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885CHEK2 4427/4885KDR 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.